Sanofi
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×0.82 | 41 |
| immunology | ×1.50 | 5 |
| rareDisease | ×1.50 | 5 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.50 | 20 |
| phase 2 | ×0.73 | 15 |
| phase 3 | ×0.89 | 11 |
| preclinical | ×1.43 | 5 |
| phase 1 | ×0.76 | 4 |
| discovery | ×0.99 | 3 |
Strategy profile
Based on 15 disclosed transactions, Sanofi concentrates its licensing activity in Immunology, Oncology, and RareDisease. Sanofi pays a 1.08x premium over market median, with the strongest premiums in Immunology (1.50x). Their most common deal structure is License, with an average disclosed value of $1.9B. Most recent activity: 2026.
Premium by therapeutic area
How Sanofi pays relative to peer medians in each TA
Pipeline coverage & gaps
Sanofi has disclosed activity in 3 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 7 | $264M | $1.4B |
| Acquisition | 4 | $3.9B | $3.9B |
| Collaboration | 2 | $115M | $1.5B |
| Co Development | 2 | $74M | $530M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | rovadicitinib | Sino Biopharmaceutical | chronic graft-versus-host disease (cGVHD) | phase_2 | $135M | $1.5B |
| 2025 | systemic mastocytosis | Blueprint Medicines | systemic mastocytosis | approved | $9.5B | $9.5B |
| 2024 | hematologic | Nurix Therapeutics | hematologic | phase_1 | $70M | $470M |
| 2024 | ulcerativeColitis | Teva Pharmaceutical | ulcerativeColitis | phase_3 | $500M | $2.0B |
| 2024 | muscular_dystrophy | Fulcrum Therapeutics | muscular_dystrophy | phase_2 | $80M | $1.1B |
| 2024 | DR-01 | Dren Bio | Systemic Lupus Erythematosus | preclinical | $300M | $1.9B |
| 2024 | cold_agglutinin_disease | Recordati (Enjaymo) | cold_agglutinin_disease | approved | $825M | $825M |
| 2024 | Plozasiran (China) | Arrowhead Pharmaceuticals | Severe hypertriglyceridemia | phase_3 | $40M | $300M |
| 2024 | respiratory infection | Novavax | respiratory infection | phase_2 | $500M | $1.2B |
| 2024 | a1at_deficiency | Inhibrx | a1at_deficiency | phase_2 | $2.2B | $2.2B |
| 2023 | lung_nsclc | Innovent Biologics | lung_nsclc | phase_3 | $300M | $2.3B |
| 2023 | autoimmune | Kymera Therapeutics | autoimmune | phase_1 | $150M | $2.0B |
| 2023 | Teplizumab (Tzield) | Provention Bio | Type 1 Diabetes | approved | $2.9B | $2.9B |
| 2023 | ALK | CureVac | Pancreatic | discovery | $14M | $188M |
| 2023 | BMP receptor-mab | Voyager Therapeutics | OCD | phase_1 | $133M | $873M |
How this is computed
For each Sanofi deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 58 disclosed deal premiums vs. peer medians. Raw premium 1.079, clamped to [0.7, 1.5].